Immune Regulation Competitors and Similar CompaniesClear all

Immune Regulation's competitors and similar companies include Solarea Bio, AventaCell, Kangstem Biotech and Sanofi.

	Immune Regulation Immune Regulation is a clinical-stage biotech company providing technologies for resetting the immune system and developing therapies for inflammatory and immunological diseases.	Solarea Bio Solarea Bio is a biotechnology company developing microbiome-based therapeutics to treat human diseases.	AventaCell AventaCell BioMedical is a company that develops human-derived products for use in cell culture and tissue regeneration.	Kangstem Biotech Kangstem Biotech (강스템바이오텍) is a biopharmaceutical company that focuses on blood-derived stem cell therapy.	Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Founding Date	Founding Date 2011	Founding Date 2017	Founding Date 2015	Founding Date 2010	Founding Date 1994
Type	Type Private	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech drug development life sciences therapy	Tags Healthcare biotech drug development life sciences therapy	Tags Healthcare biotech drug development life sciences therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy
Locations	Locations Great Shelford, GB HQ	Locations Cambridge, US HQ	Locations Atlanta, US HQ	Locations KR HQ	Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more
Employees	Employees 1810% decrease	Employees 205% increase	Employees 14	Employees 97	Employees 82,878
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ₩7.7b (FY, 2024)	Revenue (est.) €45.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ₩838.6m (FY, 2024)	Cost of goods €11.6b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ₩7.1b (FY, 2024)	Gross profit €37.6b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income (₩7.1b) (FY, 2024)	Net income €8b (FY, 2025)
Funding
Latest funding round	Latest funding round $ 52.4m (over 5 years ago)	Latest funding round $ 11.2m (over 5 years ago)	Latest funding round N/A	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 52.4m	Total funding raised $ 11.2m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 310m